---
figid: PMC7993678__aging-13-202547-g006
figtitle: Cancer associated fibroblasts (CAFs) from osimertinib-resistant patients
  promoted osimertinib resistance via HGF/MET signaling and induction of epithelial-to-mesenchymal
  transition (EMT) and transformed NSCLC cells into TKI resistant stem-like cells
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC7993678
filename: aging-13-202547-g006.jpg
figlink: pmc/articles/PMC7993678/figure/f6/
number: F6
caption: Cancer associated fibroblasts (CAFs) from osimertinib-resistant patients
  promoted osimertinib resistance via HGF/MET signaling and induction of epithelial-to-mesenchymal
  transition (EMT) and transformed NSCLC cells into TKI resistant stem-like cells.
  The treatment of capmatinib (MET inhibitor) inhibited CAF-mediated MET/Akt activation
  bypassing EGFR signaling pathway and re-sensitizing NSCLC towards osimertinib.
papertitle: MET inhibitor, capmatinib overcomes osimertinib resistance via suppression
  of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation
  of cancer-associated fibroblasts.
reftext: Kaibin Zhu, et al. Aging (Albany NY). 2021 Mar 15;13(5):6890-6903.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7941407
figid_alias: PMC7993678__F6
figtype: Figure
redirect_from: /figures/PMC7993678__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7993678__aging-13-202547-g006.html
  '@type': Dataset
  description: Cancer associated fibroblasts (CAFs) from osimertinib-resistant patients
    promoted osimertinib resistance via HGF/MET signaling and induction of epithelial-to-mesenchymal
    transition (EMT) and transformed NSCLC cells into TKI resistant stem-like cells.
    The treatment of capmatinib (MET inhibitor) inhibited CAF-mediated MET/Akt activation
    bypassing EGFR signaling pathway and re-sensitizing NSCLC towards osimertinib.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TBX1
  - HGF
  - IL6
  - SOS1
  - CXCL8
  - TGFB1
  - TGFB2
  - TGFB3
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - EGFR
  - AKT1
  - AKT2
  - AKT3
  - CTNNB1
  - SNAI1
  - Osimertinib
  - Campatinib
  - NSCLC
---
